Core Insights - Plus Therapeutics has announced a comprehensive restructuring of its previous $15 million equity financing, which eliminates the potential issuance of up to 1.5 billion shares of common stock, aiming to enhance shareholder value and simplify its equity capital structure [1][6]. Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging central nervous system cancers, with a pipeline that includes programs for leptomeningeal metastases and recurrent glioblastoma [4]. Restructuring Details - The restructuring involves the cancellation of approximately 25 million shares of common stock or pre-funded warrants, which will further reduce stockholder dilution [6]. - The company has filed a request with the SEC to withdraw the resale registration statement related to the March 2025 equity financing [3]. - Future financing provisions state that 90% of proceeds from any capital raised after July 1, 2025, will be used to repay holders of 22,727,270 shares of common stock at 115% of the original price paid, based on an effective initial price of $0.66 per share [6].